Shares of Lupin were down 4 per cent to Rs 1,165.95 on the BSE in the intra-day trade on Friday on profit booking after the company's consolidated sales declined 0.8 per cent year on year (YoY) to Rs 3,759 crore for the quarter ended March 31, 2021 (Q4FY21), led by a YoY decline in US and in API (active pharmaceutical ingredient) sales. The pharmaceutical's company had posted sales of Rs 3,791 crore in the corresponding period of FY20.
TO READ THE FULL STORY, SUBSCRIBE NOW NOW AT JUST RS 249 A MONTH.
Already a premium subscriber? LOGIN NOW
What you get on Business Standard Premium?
- Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
- Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
- Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
- Pick your 5 favourite companies, get a daily email with all news updates on them.
- 26 years of website archives.
- Preferential invites to Business Standard events.
Subscribe to Business Standard Premium
Exclusive Stories, Curated Newsletters, 26 years of Archives, E-paper, and more!
First Published: Fri, May 14 2021. 11:37 IST